The contribution of MYC and PLK1 expression to proliferative capacity in diffuse large B-cell lymphoma

References

• Lenz G, Staudt LM. Aggressive lymphomas. N Engl J Med. 2010;362:1417–1429.
   PubMed Web of Science ®Google Scholar
• Swerdlow SC, Harris NL, Jaffe ES, et al. WHO classification of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC; 2017.
   Google Scholar
• Riedell PA, Smith SM. Double hit and double expressors in lymphoma: definition and treatment. Cancer. 2018;124:4622–4632.
   PubMed Web of Science ®Google Scholar
• Swerdlow SH, Campo E, Pileri SA, et al. The 2016 revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127:2375–2390.
   PubMed Web of Science ®Google Scholar
• Meyer N, Penn LZ. Reflecting on 25 years with MYC. Nat Rev Cancer. 2008;8:976–990.
   PubMed Web of Science ®Google Scholar
• Roussel MF, Cleveland JL, Shurtleff SA, et al. Myc rescue of a mutant CSF-1 receptor impaired in mitogenic signalling. Nature. 1991;353:361–363.
   PubMed Web of Science ®Google Scholar
• Facchini LM, Penn LZ. The molecular role of Myc in growth and transformation: recent discoveries lead to new insights. FASEB J. 1998;12:633–651.
   PubMed Web of Science ®Google Scholar
• Trumpp A, Refaeli Y, Oskarsson T, et al. c-Myc regulates mammalian body size by controlling cell number but not cell size. Nature. 2001;414:768–773.
   PubMed Web of Science ®Google Scholar
• Haws BT, Cui W, Persons DL, et al. Clinical and pathologic correlation of increased MYC gene copy number in diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2016;16:679–683.
   PubMed Web of Science ®Google Scholar
• Nguyen L, Papenhausen P, Shao H. The role of c-MYC in B-cell lymphomas: diagnostic and molecular aspects. Genes (Basel). 2017;8:E116.
   PubMed Web of Science ®Google Scholar
• Petrich AM, Gandhi M, Jovanovic B, et al. Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis. Blood. 2014;124:2354–2361.
   PubMed Web of Science ®Google Scholar
• Akasaka T, Akasaka H, Ueda C, et al. Molecular and clinical features of non-Burkitt's, diffuse large-cell lymphoma of B-cell type associated with the c-MYC/immunoglobulin heavy-chain fusion gene. J Clin Oncol. 2000;18:510–518.
   PubMed Web of Science ®Google Scholar
• Ladanyi M, Offit K, Jhanwar SC, et al. MYC rearrangement and translocations involving band 8q24 in diffuse large cell lymphomas. Blood. 1991;77:1057–1063.
   PubMed Web of Science ®Google Scholar
• Kramer MH, Hermans J, Wijburg E, et al. Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. Blood. 1998;92:3152–3162.
   PubMed Web of Science ®Google Scholar
• Vitolo U, Gaidano G, Botto B, et al. Rearrangements of bcl-6, bcl-2, c-myc and 6q deletion in B-diffuse large-cell lymphoma: clinical relevance in 71 patients. Ann Oncol. 1998;9:55–61.
   PubMed Web of Science ®Google Scholar
• Kawasaki C, Ohshim K, Suzumiya J, et al. Rearrangements of bcl-1, bcl-2, bcl-6, and c-myc in diffuse large B-cell lymphomas. Leuk Lymphoma. 2001;42:1099–1106.
   PubMed Web of Science ®Google Scholar
• Karube K, Campo E. MYC alterations in diffuse large B-cell lymphomas. Semin Hematol. 2015;52:97–106.
   PubMed Web of Science ®Google Scholar
• Chisholm KM, Bangs CD, Bacchi CE, et al. Expression profiles of MYC protein and MYC gene rearrangement in lymphomas. Am J Surg Pathol. 2015;39:294–303.
   PubMed Web of Science ®Google Scholar
• Li Z-M, Huang J-J, Xia Y, et al. High Ki-67 expression in diffuse large B-cell lymphoma patients with non-germinal center subtype indicates limited survival benefit from R-CHOP therapy. Eur J Haematol. 2012;88:510–517.
   PubMed Web of Science ®Google Scholar
• Dang CV, Reddy EP, Shokat KM, et al. Drugging the ‘undruggable’ cancer targets. Nat Rev Cancer. 2017;17:502.
   PubMed Web of Science ®Google Scholar
• Ren Y, Bi C, Zhao X, et al. PLK1 stabilizes a MYC-dependent kinase network in aggressive B cell lymphomas. J Clin Invest. 2018;128:5517–5530.
   PubMed Web of Science ®Google Scholar
• Blom S, Paavolainen L, Bychkov D, et al. Systems pathology by multiplexed immunohistochemistry and whole-slide digital image analysis. Sci Rep. 2017;7.
   Web of Science ®Google Scholar
• Wahlby C, Erlandsson F, Bengtsson E, et al. Sequential immunofluorescence staining and image analysis for detection of large numbers of antigens in individual cell nuclei. Cytometry. 2002;47:32–41.
   PubMedGoogle Scholar
• Gerdes MJ, Sevinsky CJ, Sood A, et al. Highly multiplexed single-cell analysis of formalin-fixed, paraffin-embedded cancer tissue. Proc Natl Acad Sci USA. 2013;110:11982–11987.
   PubMed Web of Science ®Google Scholar
• Rigacci L, Alterini R, Bernabei PA, et al. Multispectral imaging autofluorescence microscopy for the analysis of lymph-node tissues. Photochem Photobiol. 2000;71:737–742.
   PubMed Web of Science ®Google Scholar
• Salva KA, Bennett D, Longley J, et al. Multispectral imaging approach to the diagnosis of a CD20+ cutaneous T-cell lymphoproliferative disorder. A case report. Am J Dermatopathol. 2015;37:e116–e121.
   PubMed Web of Science ®Google Scholar
• Ng SB, Fan S, Choo SN, et al. Quantitative analysis of a multiplexed immunofluorescence panel in T-cell lymphoma. SLAS Technol. 2018;23:252–258.
   PubMed Web of Science ®Google Scholar
• Wee YTF, Alkaff SMF, Lim JCT, et al. An integrated automated multispectral imaging technique that simultaneously detects and quantitates viral RNA and immune cell protein markers in fixed sections from Epstein-Barr virus-related tumours. Ann Diagn Pathol. 2018;37:12–19.
   PubMed Web of Science ®Google Scholar
• Hollman-Hewgley D, Lazare M, Bordwell A, et al. A single slide multiplex assay for the evaluation of classical Hodgkin lymphoma. Am J Surg Pathol. 2014;38:1193–1202.
   PubMed Web of Science ®Google Scholar
• Rose CJ, Naidoo K, Clay V, et al. A statistical framework for analyzing hypothesized interactions between cells imaged using multispectral microscopy and multiple immunohistochemical markers. J Pathol Inform. 2013;4:4.
   PubMedGoogle Scholar
• Huang W, Hennrick K, Drew S. A colorful future of quantitative pathology: validation of Vectra technology using chromogenic multiplexed immunohistochemistry and prostate tissue microarrays. Hum Pathol. 2013;44:29–38.
   PubMed Web of Science ®Google Scholar
• Hans CP, Weisenburger DD, Greiner TC, et al. Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2004;103:275–282.
   PubMed Web of Science ®Google Scholar
• Johnson NA, Slack GW, Savage KJ, et al. Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30:3452–3459.
   PubMed Web of Science ®Google Scholar
• Li L, Li Y, Que X, et al. Prognostic significances of overexpression MYC and/or BCL2 in R-CHOP-treated diffuse large B-cell lymphoma: a systematic review and meta-analysis. Sci Rep. 2018;8:6267.
   PubMed Web of Science ®Google Scholar
• Kluk MJ, Chapuy B, Sinha P, et al. Immunohistochemical detection of MYC-driven diffuse large B-cell lymphomas. PLoS One. 2012;7:e33813.
   PubMed Web of Science ®Google Scholar
• Barrans S, Crouch S, Smith A, et al. Rearrangement of MYC is associated with poor prognosis in patients with diffuse large B-cell lymphoma treated in the era of rituximab. J Clin Oncol. 2010;28:3360–3365.
   PubMed Web of Science ®Google Scholar
• Mationg-Kalaw E, Tan LH, Tay K, et al. Does the proliferation fraction help identify mature B cell lymphomas with double- and triple-hit translocations? Histopathology. 2012;61:1214–1218.
   PubMed Web of Science ®Google Scholar
• Obermann EC, Csato M, Dirnhofer S, et al. Aberrations of the MYC gene in unselected cases of diffuse large B-cell lymphoma are rare and unpredictable by morphological or immunohistochemical assessment. J Clin Pathol. 2009;62:754–756.
   PubMed Web of Science ®Google Scholar
• Kee N, Sivalingam S, Boonstra R, et al. The utility of Ki-67 and BrdU as proliferative markers of adult neurogenesis. J Neurosci Methods. 2002;115:97–105.
   PubMed Web of Science ®Google Scholar
• Feng Y, Lin J, Liu Y, et al. Investigation of expressions of PDK1, PLK1 and c-Myc in diffuse large B-cell lymphoma. Int J Exp Path. 2019;100:32–40.
   PubMed Web of Science ®Google Scholar
• Tan J, Li Z, Lee PL, et al. PDK1 signaling toward PLK1-MYC activation confers oncogenic transformation, tumor-initiating cell activation, and resistance to mTOR-targeted therapy. Cancer Discov. 2013;3:1156–1171.
   PubMed Web of Science ®Google Scholar
• Pulvino M, Liang Y, Oleksyn D, et al. Inhibition of proliferation and survival of diffuse large B-cell lymphoma cells by a small-molecule inhibitor of the ubiquitin-conjugating enzyme Ubc13-Uev1A. Blood. 2012;120:1668–1677.
   PubMed Web of Science ®Google Scholar
• David A, Arnaud N, Fradet M, et al. c-Myc dysregulation is a co-transforming event for nuclear factor-kappaB activated B cells. Haematologica. 2017;102:883–894.
   PubMed Web of Science ®Google Scholar
• Zhao X, Wang X, Li Q, et al. FBXL10 contributes to the development of diffuse large B-cell lymphoma by epigenetically enhancing ERK1/2 signaling pathway. Cell Death Dis. 2018;9:46.
   PubMed Web of Science ®Google Scholar
• Zhang J, Grubor V, Love CL, et al. Genetic heterogeneity of diffuse large B-cell lymphoma. Proc Natl Acad Sci USA. 2013;110:1398–1403.
   PubMed Web of Science ®Google Scholar
• Dagogo-Jack I, Shaw AT. Tumour heterogeneity and resistance to cancer therapies. Nat Rev Clin Oncol. 2018;15:81–94.
   PubMed Web of Science ®Google Scholar
• Strebhardt K. Multifaceted polo-like kinases: drug targets and antitargets for cancer therapy. Nat Rev Drug Discov. 2010;9:643.
   PubMed Web of Science ®Google Scholar
• Xiao D, Yue M, Su H, et al. Polo-like kinase-1 regulates Myc stabilization and activates a feedforward circuit promoting tumor cell survival. Mol Cell. 2016;64:493–506.
   PubMed Web of Science ®Google Scholar
• Identifier: NCT01662505. Volasertib in japanese patients with acute myeloid leukemia (AML) [Internet]. National Library of Medicine; 2012. [cited 2018 Nov 21]. Available from: https://clinicaltrials.gov/ct2/show/results/NCT01662505?term=Volasertib&rank=1
   Google Scholar
• Stadler WM, Vaughn DJ, Sonpavde G, et al. An open-label, single-arm, phase 2 trial of the polo-like kinase inhibitor volasertib (BI 6727) in patients with locally advanced or metastatic urothelial cancer. Cancer. 2014;120:976–982.
   PubMed Web of Science ®Google Scholar
• Higuchi F, Fink AL, Kiyokawa J, et al. PLK1 inhibition targets Myc-activated malignant glioma cells irrespective of mismatch repair deficiency-mediated acquired resistance to temozolomide. Mol Cancer Ther. 2018;17:2551–2563.
   PubMed Web of Science ®Google Scholar
• Choi PS, van Riggelen J, Gentles AJ, et al. Lymphomas that recur after MYC suppression continue to exhibit oncogene addiction. Proc Natl Acad Sci. 2011;108:17432–17437.
   PubMed Web of Science ®Google Scholar
• Staiger AM, Ziepert M, Horn H, et al. Clinical impact of the cell-of-origin classification and the MYC/BCL2 dual expresser status in diffuse large B-cell lymphoma treated within prospective clinical trials of the german high-grade non-Hodgkin's lymphoma study group. J Clin Oncol. 2017;35:2515–2526.
   PubMed Web of Science ®Google Scholar
• Green TM, Young KH, Visco C, et al. Immunohistochemical double-hit score is a strong predictor of outcome in patients with diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone. J Clin Oncol. 2012;30:3460–3467.
   PubMed Web of Science ®Google Scholar
• Kluk MJ, Ho C, Yu H, et al. MYC immunohistochemistry to identify MYC-Driven B-cell lymphomas in clinical practice. Am J Clin Pathol. 2016;145:166–179.
   PubMed Web of Science ®Google Scholar
• Mahmoud AZ, George TI, Czuchlewski DR, et al. Scoring of MYC protein expression in diffuse large B-cell lymphomas: concordance rate among hematopathologists. Mod Pathol. 2015;28:545–551.
   PubMed Web of Science ®Google Scholar
• Rizzardi AE, Johnson AT, Vogel RI, et al. Quantitative comparison of immunohistochemical staining measured by digital image analysis versus pathologist visual scoring. Diagn Pathol. 2012;7:42.
   PubMed Web of Science ®Google Scholar
• Kalra J, Baker J. Multiplex immunohistochemistry for mapping the tumor microenvironment. Methods Mol Biol. 2017;1554:237–251.
   PubMedGoogle Scholar